| 哈斯高娃,曹中朝,刘东华,张 勇,乌吉斯古楞.利伐沙班与华法林对高龄非瓣膜性房颤患者D-二聚体、NT-proBNP水平的影响[J].现代生物医学进展英文版,2017,17(32):6291-6294. |
| 利伐沙班与华法林对高龄非瓣膜性房颤患者D-二聚体、NT-proBNP水平的影响 |
| Effects of Rivaroxaban and Warfarin on D-dimer and NT-proBNP Levels in Elderly Patients with NVAF |
| Received:June 12, 2017 Revised:July 10, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.32.019 |
| 中文关键词: 非瓣膜性房颤 高龄患者 利伐沙班 华法林 D-二聚体 N末端B型利钠肽原 |
| 英文关键词: Non-valvular atrial fibrillation Elderly patient Rivaroxaban Warfarin D-dimer N-terminal pro-brain natriuretic peptide |
| 基金项目:内蒙古自治区自然科学基金项目（2012MS121） |
|
| Hits: 177 |
| Download times: 145 |
| 中文摘要: |
| 摘要 目的：探讨利伐沙班与华法林对高龄非瓣膜性房颤(NVAF)患者血浆D-二聚体(D-D)、N末端B型利钠肽原(NT-proBNP)水平的影响及其临床疗效。方法：选取我院2015年1月~2016年11月收治的146例高龄NVAF患者，采取随机数字表法均分为两组。华法林组予以华法林抗栓治疗，利伐沙班组采取利伐沙班抗栓治疗。记录比较两组治疗期间栓塞、出血情况及不良反应，以及治疗前后血浆D-二聚体(D-D)、N末端B型利钠肽原(NT-proBNP)水平的变化情况。结果：两组治疗后栓塞发生率比较，差异无统计学意义(P>0.05)。利伐沙班组出血发生率（4.1%）低于华法林组（15.1%），差异具有统计学意义（P<0.05)。与治疗前相比，两组治疗后血浆D-D和NT-proBNP水平均降低，差异具有统计学意义(P<0.01)；治疗后，两组血浆D-D和NT-proBNP水平比较，差异无统计学意义(P>0.05)。两组不良反应发生率对比，差异无统计学意义(P>0.05)。结论：与华法林相比，高龄非瓣膜性房颤应用利伐沙班抗栓治疗在患者耐受性与预防血栓栓塞方面优势相当，但利伐沙班更能有效降低患者出血风险。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect of rivaroxaban and warfarin on the serum levels of D-dimer (D-D) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in elderly patients with non-valvular atrial fibrillation (NVAF). Methods: 146 cases with NVAF who were treated in our hospital from January 2015 to November 2016 were selected and randomly divided into two groups. The warfarin group was treated with warfarin, while the rivaroxaban group was treated with rivaroxaban. Then the occurrence of embolism, the hemorrhage, the adverse reactions and the changes of plasma D-D and NT-proBNP of patients in the two groups were observed and compared before and after the treatment. Results: After treatment, there was no statistically significant difference about the incidence of embolism in the two groups (P>0.05). The incidence of hemorrhage in the rivaroxaban group was 4.1%, which was lower than 15.1% of the warfarin group, and the difference was statistically significant (P<0.01). After treatment, the plasma D-D and NT-proBNP levels in the two groups were lower than before (P<0.01); There was no statistically significant difference about the changes of plasma D-D and NT-proBNP levels in the two groups (P>0.05). There was no statistically significant difference about the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The clinical effect of rivaroxaban and warfarin are equal in terms of the tolerance and thromboembolism prevention of elderly patients with nonvalvular atrial fibrillation, while rivaroxaban is more effective in reducing bleeding risk. |
|
View Full Text
View/Add Comment Download reader |
| Close |
